Peptide Power: Harmonizing Liver Disease

A GLOBAL HEALTH CHALLENGE WITH LIMITED TREATMENT OPTIONS

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), previously known as NAFLD, and its severe form, steatohepatitis (MASH), affect over 25% of the global population. Despite recent advances, there are still no widely effective therapies to halt disease progression, leaving millions at risk of fibrosis, cirrhosis, and liver cancer.

PROBLEM

OUR SOLUTION

NOVEL PEPTIDE THERAPY TARGETING DISEASE PROGRESSION

LIFESOMIX is developing a first-in-class therapy based on SOCS1-derived peptidomimetics. Our approach mimics a key endogenous regulator of the JAK/STAT pathway to selectively modulate dysregulated signaling and restore immune and metabolic balance. By targeting a central driver of disease progression, our peptides reduce inflammation, lipid accumulation, and fibrosis.

Péptidos SOCS1 hepatoprotectores

New therapeutic peptides slow the progression of metabolic fatty liver disease.

A new family of therapeutic peptides has demonstrated protective effects against metabolic dysfunction-associated fatty liver disease (MASLD)

CIBER research group

ANNOUNCEMENT

Lifesomix Features

Advancing new therapies to transform chronic liver disease

Selective modulation of inflammatory pathways and liver metabolism.

Innovative Mechanism

Proven Safety & Efficacy

Preclinical studies show up to a 40% reduction in liver damage

Competitive Edge

A novel SOCS1-based peptidomimetic strategy targeting a central regulator of disease progression

Strong IP Protection

Patent applications covering Europe and major international markets

Scalability

Advancing preclinical development toward first-in-human studies